[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.83.210. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
April 13, 2011

Infection Prevention and Comparative Effectiveness Research

Author Affiliations

Author Affiliations: Division of General Internal Medicine, University of Iowa, Carver College of Medicine and Center for Comprehensive Access & Delivery Research and Evaluation (CADRE), Iowa City VA Medical Center, Iowa City (Dr Perencevich); and Department of Medicine and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia (Dr Lautenbach).

JAMA. 2011;305(14):1482-1483. doi:10.1001/jama.2011.450

Health care–acquired infections, particularly those due to antimicrobial-resistant bacteria, have received significant attention in recent years. Despite work focused on elucidating the epidemiology and effects of such infections, success in curbing their emergence remains elusive. Few new classes of antibiotics are even in the earliest stages of development, making efforts to prevent the emergence and spread of antimicrobial-resistant bacteria even more crucial. However, the evidence base on which potential infection-prevention strategies must be built is severely limited because very few of the necessary clinical trials have been conducted. The generation of such scientific evidence is constrained by the perceived difficulty of completing the necessary studies and limited federal funding available for assessing infection-prevention interventions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×